Number of pages: 100 | Report Format: PDF | Published date: March 29, 2023
Historical Years – 2021 | Base Year – 2022 | Forecasted Years – 2023-2031
Report Attribute |
Details |
CAGR |
4.1% |
Base Year for Estimation |
2022 |
Forecast Period |
2023-2031 |
Historical Year |
2022 |
Segments Covered |
Therapy Type, Drug Class, End-user, and Region |
Regional Scope |
North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa |
According to the deep-dive market assessment study by Growth Plus Reports, the global pediatric osteosarcoma therapeutics market is expected to register a revenue CAGR of 4.1% during the forecast period of 2023 to 2031.
Pediatric Osteosarcoma Therapeutics Market Fundamentals
Pediatric osteosarcoma therapeutics refers to the various medical treatments used to manage and treat pediatric osteosarcoma, a type of bone cancer primarily affecting children and adolescents. The treatment approach for pediatric osteosarcoma typically involves a combination of chemotherapy, including antineoplastic agents, antiemetic agents, colony-stimulating factors, and antidotes. In some cases, additional treatments, such as targeted therapy and immunotherapy, may also be used. The specific therapeutic approach will depend on several factors, including the extent and location of the tumor and the child’s age and overall health. A team of specialists, including pediatric and radiation oncologists, usually provides the treatment. Pediatric osteosarcoma therapeutics aim to eradicate the tumor and any surrounding cancer cells while minimizing the potential for long-term side effects and preserving the child’s quality of life.
Pediatric Osteosarcoma Therapeutics Market Dynamics
The rising prevalence of pediatric osteosarcoma globally increases the demand for pediatric osteosarcoma therapeutics. Pediatric osteosarcoma is the third most common type of cancer in adolescence. The development of targeted therapies and immunotherapies is expected to transform the treatment of pediatric osteosarcoma, offering new treatment options for patients and boosting the revenue growth of the pediatric osteosarcoma therapeutics market. For instance, in September 2022, Radiopharm Theranostics received FDA orphan drug designation (ODD) for DUNP19 to treat osteosarcoma. DUNP19, a dual-action, LRRC15-targeted monoclonal antibody, is a first-of-its-kind treatment with dual-action tumor targeting that aims to locate, internalize, and eradicate cancer cells and cells in the tumor microenvironment. More than 50% of tumor masses comprise these cells, including immune and stromal cells.
Governments worldwide are increasing their funding for cancer research, particularly in developing countries. This is driving the development of new treatments for pediatric osteosarcoma and other types of cancer. Moreover, the demand for personalized medicine is increasing globally, with patients seeking more targeted and individualized treatments. This is expected to drive the development of new personalized therapies for pediatric osteosarcoma. The growing awareness of pediatric osteosarcoma among healthcare professionals and patients is expected to drive demand for effective treatments. Early detection and diagnosis of the disease are critical to improving treatment outcomes, and increased awareness can help improve detection rates.
However, the cost of treatment for pediatric osteosarcoma is high, restricting the revenue growth of the pediatric osteosarcoma therapeutics market. The development and obtaining regulatory approval for new therapies for pediatric osteosarcoma can be a lengthy and costly process, hindering the revenue growth of the pediatric osteosarcoma therapeutics market.
Pediatric Osteosarcoma Therapeutics Market Ecosystem
The global pediatric osteosarcoma therapeutics market is analyzed from four perspectives: therapy type, drug class, end-user, and region.
Pediatric Osteosarcoma Therapeutics Market by Therapy Type
[86855]
Based on the therapy type, the global pediatric osteosarcoma therapeutics market is segmented into monotherapy and combination therapy.
The combination therapy segment accounts for a considerable revenue share of the pediatric osteosarcoma therapeutics market. Combination therapy has become the standard of care for pediatric osteosarcoma treatment, as it is effective in multiple clinical trials. Combination therapy involves using two or more drugs with different mechanisms of action. This approach can increase the overall effectiveness of treatment by targeting multiple pathways involved in tumor growth and progression. Combination therapy has been shown to improve overall survival rates and reduce the risk of disease recurrence compared to single-agent therapy. By using a combination of drugs, the likelihood of tumor cells developing resistance to treatment is reduced, as it is less likely that all the drugs will be affected by the same resistance mechanism, increasing the demand for combination therapy.
Pediatric Osteosarcoma Therapeutics Market by Drug Class
Based on the drug class, the global pediatric osteosarcoma therapeutics market is segmented into chemotherapy and targeted therapy.
The chemotherapy segment dominates the pediatric osteosarcoma therapeutics market with the largest revenue share. The chemotherapy segment is further sub-segmented into antineoplastic agents, antiemetic agents, colony-stimulating factors, and antidotes. Antineoplastic agents are the primary treatment for pediatric osteosarcoma. Antineoplastic agents have demonstrated significant efficacy in clinical trials, leading to their adoption as the standard of care for pediatric osteosarcoma treatment, boosting segment revenue growth. There are currently several FDA-approved antineoplastic agents for treating pediatric osteosarcoma, including Doxorubicin, Cisplatin, Methotrexate, and Ifosfamide. Antineoplastic agents are often combined with other drugs, such as immunotherapy or targeted therapy, to enhance their efficacy and improve patient outcomes. There is ongoing research and development in the antineoplastic agents segment, with new drugs and drug combinations being explored to further improve treatment outcomes for pediatric osteosarcoma patients.
The targeted therapy segment is expected to register a lucrative revenue growth rate during the forecast period. Targeted therapy drugs are becoming increasingly adopted in treating pediatric osteosarcoma, contributing to this segment’s revenue growth. Targeted therapy drugs have demonstrated significant efficacy in clinical trials, leading to their adoption as a treatment option for pediatric osteosarcoma. Targeted therapy drugs are sometimes combined with conventional therapeutics for personalized treatment design.
Pediatric Osteosarcoma Therapeutics Market by End-user
Based on the end-user, the global pediatric osteosarcoma therapeutics market is segmented into specialty hospitals, cancer institutes, and others.
The specialty hospitals segment accounts for a measurable revenue share of the pediatric osteosarcoma therapeutics market. Specialty hospitals are dedicated to treating specific conditions and diseases, including pediatric osteosarcoma. This specialization allows for developing specialized treatment protocols and expertise, leading to improved patient outcomes. Pediatric oncologists, surgeons, and other medical specialists frequently collaborate in multidisciplinary teams at specialty hospitals to offer patients with pediatric osteosarcoma comprehensive care. Specialized hospitals generally include cutting-edge amenities, such as state-of-the-art imaging and radiation therapy technology, enabling them to offer the most efficient treatments for pediatric osteosarcoma patients. Specialty hospitals are easier for patients and families to approach as many insurance policies are covered there.
The cancer institutes segment also accounts for a significant revenue share of the pediatric osteosarcoma therapeutics market. Cancer institutes are specialized healthcare facilities with expertise in diagnosing, treating, and managing cancer, including pediatric osteosarcoma. Cancer institutes often conduct research and clinical trials to advance the understanding of pediatric osteosarcoma and develop new treatment options, which can further improve patient outcomes. Cancer institutes usually have established referral networks with other healthcare facilities, which enables them to receive patients from other facilities and provide specialized care for pediatric osteosarcoma patients.
Pediatric Osteosarcoma Therapeutics Market by Region
Geographically, the global pediatric osteosarcoma therapeutics market has been segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.
North America dominated the pediatric osteosarcoma therapeutics market with the largest revenue share in 2022. North America has a higher incidence of pediatric osteosarcoma, leading the regional revenue growth. According to the American Society of Clinical Oncology (ASCO) in the U.S., osteosarcoma makes up 2% of all cancers in children ages 0 to 14 and 3% of all cancers in teens ages 15 to 19. North America has a well-developed healthcare infrastructure, including specialty hospitals, research institutions, and pharmaceutical companies, enabling advanced therapeutics development and delivery. The regulatory environment in North America is favorable for developing and approving new therapeutics, which incentivizes pharmaceutical companies to invest in research and development. North America is home to many leading research institutions and pharmaceutical companies, which conduct research and development to advance the understanding and treatment of pediatric osteosarcoma, propelling the region’s revenue growth.
Pediatric Osteosarcoma Therapeutics Market Competitive Landscape
The prominent players operating in the global pediatric osteosarcoma therapeutics market are:
Pediatric Osteosarcoma Therapeutics Market Strategic Developments
Pediatric osteosarcoma therapeutics refer to the various medical treatments used to manage and treat pediatric osteosarcoma, a type of bone cancer primarily affecting children and adolescents.
The rising prevalence of pediatric osteosarcoma worldwide and increasing R&D related to targeted therapy and immunotherapy are some of the driving factors in the market.
The prominent players operating in the global pediatric osteosarcoma therapeutics market are Pfizer Inc., Bristol-Myers Squibb Company, Merck & Co., GlaxoSmithKline plc, and Teva Pharmaceutical Industries Ltd.
The chemotherapy segment dominates the global pediatric osteosarcoma therapeutics market.
The high treatment cost and stringent regulatory framework are some of the restricting factors of the market.
*Insights on financial performance are subject to the availability of information in the public domain